Xeris Biopharma (XERS) Stock: Buy, Sell, or Hold?
XERS - Xeris Biopharma Holdings, Inc. Common Stock
$7.45
-0.22 (-2.87%)
▼
5d:
-13.27%
30d:
-12.25%
90d:
+7.5%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When XERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: XERS is down 13.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: XERS is down 13.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.60
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.58
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XERS is currently trading at $7.45, which is considered oversold relative to its 30-day fair value range of $7.95 to $8.74. The stock's valuation (Forward PE: 19.1) is in line with its historical norms (19.4). Remarkably, the market is currently pricing in an annual earnings decline of 0.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, XERS is showing support break momentum. The price is currently testing key support at $7.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: XERS scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.71 (+57.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XERS is showing support break momentum. The price is currently testing key support at $7.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: XERS scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.71 (+57.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.95 -
$8.74
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (28/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 57.2% below Wall St target ($11.71)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.95 -
$8.74
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.40
Resistance Level
$8.78
Current Trend
Support Break
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.10
Wall Street Target
$11.71
(+57.2%)
Revenue Growth (YoY)
28.7%
Profit Margin
-5.1%
Valuation Discount vs History
-0.4% cheaper
PE vs Historical
19.1 vs 19.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.4%
(market-implied from PE analysis)
1-Year Target
$7.42
(0%)
2-Year Target
$7.39
(-1%)
3-Year Target
$7.36
(-1%)
3-Yr Target (if PE normalizes)
(PE: 19→19)
$7.48
(+0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 19.1 to 19.4
Stabilization Target:
$7.57
(+1.6%)
PE Expansion Potential:
+1.6%
Share & Embed Analysis
Last updated: September 13, 2026 7:17 PM ET
Data refreshes hourly during market hours. Next update: 8:17 PM
Data refreshes hourly during market hours. Next update: 8:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Beth Hecht
SELL
16667 shares
2026-04-01
James Aloysius Brady
SELL
10834 shares
2026-03-30
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |